Evidence map›Paper›PMID 35620517›Full record

ArticleFrontiers in cardiovascular medicine2022

Anemoside B4 Inhibits Vascular Smooth Muscle Cell Proliferation, Migration, and Neointimal Hyperplasia.

Dan Shan, Ping Qu, Chao Zhong, Luling He, Qingshan Zhang, Guoyue Zhong, Wenhui Hu, Yulin Feng, Shilin Yang, Xiao-Feng Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Rosuvastatin activates autophagyThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Dan ShanCenter for Translational Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Ping QuDepartment of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Chao ZhongCenter for Translational Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Luling HeCenter for Translational Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Qingshan ZhangDepartment of Internal Medicine, Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao, China.
Guoyue ZhongResearch Center of Natural Resources of Chinese Medicinal Materials and Ethnic Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Wenhui HuDepartment of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Yulin FengThe National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Nanchang, China.
Shilin YangThe National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Nanchang, China.
Xiao-Feng YangDepartment of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Jun YuDepartment of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States.
Temple University · USJiangxi University of Traditional Chinese Medicine · CNInner Mongolia University for Nationalities · CN

Funding

CD4 T cell-targeted nanoparticle in vivo delivery of CRISPR/Cas9 genome editors for HIV cureR01AI145034 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI HU, WENHUI · 2019 to 2023
$3.8M
American Heart Association-American Stroke Association 18EIA33900065NIAID NIH HHS R01 AI145034
6 · The paper itself

Abstract

Vascular smooth muscle cell (VSMC) phenotypic transformation, proliferation, and migration play a pivotal role in developing neointimal hyperplasia after vascular injury, including percutaneous transluminal angioplasty and other cardiovascular interventions. Anemoside B4 (B4) is a unique saponin identified from the Pulsatilla chinensis (Bge.) Regel, which has known anti-inflammatory activities. However, its role in modulating VSMC functions and neointima formation has not been evaluated. Herein, we demonstrate that B4 administration had a potent therapeutic effect in reducing neointima formation in a preclinical mouse femoral artery endothelium denudation model. Bromodeoxyuridine incorporation study showed that B4 attenuated neointimal VSMC proliferation

Indexed as

Anemoside B4migrationneointimal hyperplasiaproliferationvascular smooth muscle cell

Identifiers

PMID35620517
PMCPMC9127303
OpenAlexW4229442070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.